Stay informed with the latest company announcements, scientific publications, clinical milestones, media coverage, conferences, partnerships, and events from Helio Genomics.
Our landmark CLiMB trial — the largest prospective, multicenter U.S. study of its kind — is now peer-reviewed and published, demonstrating HelioLiver's superior sensitivity for early-stage HCC versus ultrasound.
Read Full StoryA strategic commercial partnership to accelerate national adoption of HelioLiver.
Read moreDr. Bharat Tewarie on where the company and the field are headed.
Watch the interviewExpanding access to our epigenomic blood test for liver cancer.
Read moreNew data on the performance of HelioLiver in early-stage HCC detection.
Read moreHighlighting the ECLIPSE platform and the HelioLiver algorithm.
Read moreA machine-learning methylation model for early cancer detection.
Read moreNo articles match your search.
Join the Helio Genomics team at upcoming conferences, symposiums, and webinars across the field.
Presenting new HelioLiver liver cancer surveillance data from the CLiMB program.
RegisterPanel discussion on blood-based multi-omics for early cancer detection.
RegisterA clinical webinar for providers on integrating HelioLiver into routine care.
RegisterNearly a decade of foundational research in DNA methylation and blood-based early cancer detection.
Subscribe to receive the latest Helio Genomics news, scientific breakthroughs, and event announcements.